- Why use Innovation Place
- Funds for r&d
- About us
- PNO services
About the Technology
Antibody-drug conjugate is one of the most important approaches in current cancer drug development. ADC is a tripartite molecule comprising a tumor-specific monoclonal antibody conjugated to a potent cytotoxin via a proprietary stable linking technology. ADC can target the tumor cells through the antibody part by recognizing and binding to a corresponding tumor antigen. After internalization, the ADC will be cleaved or digested in lysosome or endosome, and then the linked cytotoxic drugs are released to kill the cancer cells.
The candidate compound of ADC showed great tumor inhibition via a novel target, and belongs to a first-in-class drug for cancer treatment.
Application/ Indication: Cancer therapy
About the organisation
A Taiwanese non-profit biomedical research institute funded both by public and private sectors with a mission to facilitate the development of Taiwan’s biotech industry. The R&D activity of the institute focuses on preclinical development and translational research of new drug development both in biologics/ADC and small molecules. The institute also collaborates with the industry, the academic research institutes, and the hospitals both in Taiwan and in the world to help add value to the technologies, products, and services as well as assist with the business development.
Advantages & innovations
The product is a first-in-class anti-Globo H antibody-drug conjugates with the following advantages and innovations: ü High affinity and fast internalization ü Great tumor growth inhibition (>90% at 3mpk) ü Proprietary tri-mannosyl conjugation technology applied ü Uniformed DAR ratio (4) achieved via a stable and fixed linker
Stage of development
Under development/lab tested
The research institute is seeking partner for licensing, co-development, and/or contract service. They are seeking partners from the industry, academia, research organization and business to: - Enter into preclinical R&D collaboration - Further development until clinical proof-of-concept - Out-licensing
Contact/ source: Enterprise Europe Network (europa.eu)
IF YOU ARE INTERESTED IN KNOWING MORE ABOUT THIS PROJECT PLEASE REGISTER AS FREE MEMBER OR LOGIN IF ALREADY REGISTERED